Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of The Carillon Mitral Contour System® September 28, 2020
Cardiac Dimensions Announces Australian Therapeutic Goods Administration’s Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation September 2, 2020
Cardiac Dimensions Hires Gretchen Gary as Vice President of Global Therapy Development March 6, 2020
Additional Press Releases
REDUCE FMR Study Shows Cardiac Dimensions’ Carillon System Significantly Improves Mitral Regurgitation and Slows Worsening of Heart Failure September 12, 2019
Cardiac Dimensions Reaches 1,000 Implants of Carillon System, a Minimally Invasive Treatment for Functional Mitral Regurgitation July 1, 2019
New Data Shows The Carillon Mitral Contour System® Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting June 13, 2019
New Data Confirms Cardiac Dimensions’ Carillon System Provides Acute Hemodynamic Efficacy in Patients with Functional Mitral Regurgitation April 26, 2019
Cardiac Dimensions Announces DRG Reimbursement Code for Carillon Mitral Contour System® in Germany October 18, 2018
In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume September 24, 2018
This #NHEW2020, our focus is on the importance of expanding #heartfailure education throughout our communities. Implementing this is critical to improving cardiovascular health literacy and health outcomes.
Read more here: https://t.co/NelFRd8F9H https://t.co/kt8SInaVb9
New publication by Dr. Janusz Lipiecki in @ESC_Journals shows patients treated with #Carillondevice had excellent survival rate through 6+ years and sustained improvements in #FMR, LV volume, ejection fraction, and clinical status through 6+ years.